Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...
LGBTQ+ seniors are also affected by problematic rhetoric and language that belittles and dehumanizes queer experiences, says ...
Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Sage Therapeutics in a ...
Needham & Company LLC reiterated their hold rating on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a research report report published on Wednesday,Benzinga reports. Other equities ...
Highlights,Institutional investors have adjusted their holdings in Sage Therapeutics.,The company reported a negative net ...
In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The ...
Sage Therapeutics, Inc. SAGE reported a loss of $1.56 per share for the fourth quarter of 2024, wider than the Zacks ...
Canaccord Genuity has adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) by reducing the stock's price target to $8.00 from the previous $9.00, while maintaining a Hold rating on the shares. The ...